Cellular immunity to the Her-2/neu protooncogene

Advances in Cancer Research

Volumn 85, Issue , 2002, Pages 101-144

  Kiessling, Rolf ^a   Wei, W Z ^b   Herrmann, F ^c   Lindencrona, J A ^a   Choudhury, A ^a   Kono, K ^d   Seliger, B ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b WAYNE STATE UNIVERSITY   (United States)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CANCER VACCINE; CD4 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEU DIFFERENTIATION FACTOR; ONCOPROTEIN; PEPTIDE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY RESPONSE; BREAST CANCER; CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MODEL; CELL TRANSFORMATION; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG INDUCED DISEASE; DRUG RESPONSE; EPITHELIUM CELL; GENE OVEREXPRESSION; HLA SYSTEM; HUMAN; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TUMOR ESCAPE; VACCINATION;

EID: 0036391523     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(02)85004-7     Document Type: Review

References (170)

1. Abrams, S. I., Stanziale, S. F., Lunin, S. D., Zaremba, S., and Schlom, J. (1996). Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses. Eur. J. Immunol. 26, 435-443.
2. Akbari, O., Panjwani, N., Garcia, S., Tascon, R., Lowrie, D., and Stockinger, B. (1999). DNA vaccination: Transfection and activation of dendritic cells as key events for immunity. J. Exp. Med. 189, 169-178.
3. Albanell, J., and Baselga, J. (2001). Unraveling resistance to trastuzumab (Herceptin): Insulin-like growth factor-I receptor, a new suspect. J. Natl. Cancer Inst. 93, 1830-1832.
4. Alexander, J., Fikes, J., Hoffman, S., Franke, E., Sacci, J., Appella, E., Chisari, F. V., Guidotti, L. G., Chesnut, R. W., Livingston, B., and Sette, A. (1998). The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol. Res. 18, 79-92.
5. al-Kasspooles, M., Moore, J. H., Orringer, M. B., and Beer, D. G. (1993). Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int. J. Cancer 54, 213-219.
6. Amici, A., Smorlesi, A., Noce, G., Santoni, G., Cappelletti, P., Capparuccia, L., Coppari, R., Lucciarini, R., Petrelli, C., and Provinciali, M. (2000). DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther. 7, 703-706.
7. Amici, A., Venanzi, F. M., and Concetti, A. (1998). Genetic immunization against neu/erbB2 transgenic breast cancer. Cancer Immunol. Immunother. 47, 183-190.
8. Bai, A., and Forman, J. (1997). The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules. J. Immunol. 159, 2139-2146.
9. Banchereau, J., Palucka, A. K., Dhodapkar, M., Burkeholder, S., Taquet, N., Rolland, A., Taquet, S., Coquery, S., Wittkowski, K. M., Bhardwaj, N., Pineiro, L., Steinman, R., and Fay, J. (2001). Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61, 6451-6458.
10. Baselga, J. (2001). Herceptin((R)) alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trials. Oncology 61(Suppl S2), 14-21.
11. Beckhardt, R. N., Kiyokawa, N., Xi, L., Liu, T. J., Hung, M. C., el-Naggar, A. K., Zhang, H. Z., and Clayman, G. L. (1995). HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 121, 1265-1270.
12. Birner, P., Oberhuber, G., Stani, J., Reithofer, C., Samonigg, H., Hausmaninger, H., Kubista, E., Kwasny, W., Kandioler-Eckersberger, D., Gnant, M., and Jakesz, R. (2001). Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin. Cancer Res. 7, 1669-1675.
13. Boon, T., and van der Bruggen, P. (1996). Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725-729.
14. Bouchard, L., Lamarre, L., Tremblay, P. J., and Jolicoeur, P. (1989). Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57, 931-936.
15. Braun, S., Schlimok, G., Heumos, I., Schaller, G., Riethdorf, L., Riethmuller, G., and Pantel, K. (2001). ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res. 61, 1890-1895.
16. Brien, T. P., Depowski, P. L., Sheehan, C. E., Ross, J. S., and McKenna, B. J. (1998). Prognostic factors in gastric cancer. Mod. Pathol. 11, 870-877.
17. Brodowicz, T., Wiltschke, C., Budinsky, A. C., Krainer, M., Steger, G. G., and Zielinski, C. C. (1997). Soluble HER-1/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int. J. Cancer 73, 875-879.
18. Brossart, P., and Bevan, M. J. (1997). Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: Pathway of presentation and regulation by cytokines. Blood 90, 1594-1549.
19. Brossart, P., Stuhler, G., Flad, T., Stevanovic, S., Rammensee, H. G., Kanz, L., and Brugger, W. (1998). Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 58, 732-736.
20. Brossart, P., Wirths, S., Stuhler, G., Reichardt, V. L., Kanz, L., and Brugger, W. (2000). Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96, 3102-3108.
21. Cabrera, T., Angustias Fernandez, M., Sierra, A., Garrido, A., Herruzo, A., Escobedo, A., Fabra, A., and Garrido, F. (1996). High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum. Immunol. 50, 127-134.
22. Castilleja, A., Ward, N. E., O'Brian, C. A., Swearingen, B., 2nd, Swan, E., Gillogly, M. A., Murray, J. L., Kudelka, A. P., Gershenson, D. M., and Ioannides, C. G. (2001). Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity. Mol. Cell. Biochem. 217, 21-33.
23. Chaux, P., Luiten, R., Demotte, N., Vantomme, V., Stroobant, V., Traversari, C., Russo, V., Schultz, E., Cornelis, G. R., Boon, T., and van der Bruggen, P. (1999). Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J. Immunol. 163, 2928-2936.
24. Chen, Y., Hu, D., Eling, D. J., Robbins, J., and Kipps, T. J. (1998). DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res. 58, 1965-1971.
25. Chien, K. R. (2000). Myocyte survival pathways and cardiomyopathy: Implications for trastuzumab cardiotoxicity. Semin. Oncol. 27, 9-14; discussion 92-100.
26. Chiller, J. M., Habicht, G. S., and Weigle, W. O. (1971). Kinetic differences in unresponsiveness of thymus and bone marrow cells. Science 171, 813-815.
27. Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., and Slamon, D. J. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648.
28. Cohen, J. A., Weiner, D. B., More, K. F., Kokai, Y., Williams, W. V., Maguire, H. C. Jr., LiVolsi, V. A., and Greene, M. I. (1989). Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene 4, 81-88.
29. Concetti, A., Amici, A., Petrelli, C., Tibaldi, A., Provinciali, M., and Venanzi, F. M. (1996). Autoantibody to p185erbB2/neu oncoprotein by vaccination with xenogenic DNA. Cancer Immunol. Immunother. 43, 307-315.
30. Coussens, L., Yang-Feng, T. L., Liao, Y. C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230, 1132-1139.
31. Cuello, M., Ettenberg, S. A., Clark, A. S., Keane, M. M., Posner, R. H., Nau, M. M., Dennis, P. A., and Lipkowitz, S. (2001). Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 61, 4892-4900.
32. De Potter, C. R., Van Daele, S., Van de Vijver, M. J., Pauwels, C., Maertens, G., De Boever, J., Vandekerckhove, D., and Roels, H. (1989). The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology 15, 351-362.
33. Dick, T. P., Ruppert, T., Groettrup, M., Kloetzel, P. M., Kuehn, L., Koszinowski, U. H., Stevanovic, S., Schild, H., and Rammensee, H. G. (1996). Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell 86, 253-262.
34. Disis, M. L., Bernhard, H., Shiota, E M., Hand, S. L., Gralow, J. R., Huseby, E. S., Gillis, S., and Cheever, M. A. (1996a). Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines. Blood 88, 202-210.
35. Disis, M. L., Calenoff, E., McLaughlin, G., Murphy, A. E., Chen, W., Groner, B., Jeschke, M., Lydon, N., McGlynn, E., Livingston, R. B., et al. (1994). Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54, 16-20.
36. Disis, M. L., and Cheever, M. A. (1998). HER-2/neu oncogenic protein: Issues in vaccine development. Crit. Rev. Immunol. 18, 37-45.
37. Disis, M. L., Grabstein, K. H., Sleath, P. R., and Cheever, M. A. (1999). Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 5, 1289-1297.
38. Disis, M. L., Gralow, J. R., Bernhard, H., Hand, S. L., Rubin, W. D., and Cheever, M. A. (1996b). Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J. Immunol. 156, 3151-3158.
39. Disis, M. L., Knutson, K. L., McNeel, D. G., Davis, D., and Schiffman, K. (2001). Clinical translation of peptide-based vaccine trials: The HER-2/neu model. Crit. Rev. Immunol. 21, 263-273.
40. Engelhard, V. H. (1994). Structure of peptides associated with class I and class II MHC molecules. Annu. Rev. Immunol. 12, 181-207.
41. Epperson, D. E., Arnold, D., Spies, T., Cresswell, P., Pober, J. S., and Johnson, D. R. (1992). Cytokines increase transporter in antigen processing-1 expression more rapidly than HLA class I expression in endothelial cells. J. Immunol. 149, 3297-3301.
42. Falk, K., Rotzschke, O., Stevanovic, S., Gnau, V., Sparbier, K., Jung, G., Rammensee, H. G., and Walden, P. (1994). Analysis of a naturally occurring HLA class I-restricted viral epitope. Immunology 82, 337-342.
43. Ferrone, S., and Marincola, F. M. (1995). Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16, 487-494.
44. Fisk, B., Blevins, T. L., Wharton, J. T., and Ioannides, C. G. (1995). Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. 181, 2109-2117.
45. Foy, T. M., Bannink, J., Sutherland, R. A., McNeill, P. D., Moulton, G. G., Smith, J., Cheever, M. A., and Grabstein, K. (2001). Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor. Vaccine 19, 2598-2606.
46. Gajewski, T. F., Fallarino, F., Ashikari, A., and Sherman, M. (2001). Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin. Cancer Res. 7, 895s-901s.
47. Galang, C. K., Garcia-Ramirez, J., Solski, P. A., Westwick, J. K., Der, C. J., Neznanov, N. N., Oshima, R. G., and Hauser, C. A. (1996). Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation. J. Biol. Chem. 271, 7992-7998.
48. Gilboa, E. (1999). The makings of a tumor rejection antigen. Immunity 11, 263-270.
49. Gjertsen, M. K., and Gaudernack, G. (1998). Mutated Ras peptides as vaccines in immunotherapy of cancer. Vox Sang. 74, 489-495.
50. Graus-Porta, D., Beerli, R. R., Daly, J. M., and Hynes, N. E. (1997). ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16, 1647-1655.
51. Griffith, T. S., and Lynch, D. H. (1998). TRAIL: A molecule with multiple receptors and control mechanisms. Curr. Opin. Immunol. 10, 559-563.
52. Groettrup, M., Soza, A., Eggers, M., Kuehn, L., Dick, T. P., Schild, H., Rammensee, H. G., Koszinowski, U. H., and Kloetzel, P. M. (1996). A role for the proteasome regulator PA28alpha in antigen presentation. Nature 381, 166-168.
53. Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., and Muller, W. J. (1992). Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 89, 10,578-10,582.
54. Halapi, E., Yamamoto, Y., Juhlin, C., Jeddi-Tehrani, M., Grunewald, J., Andersson, R., Hising, C., Masucci, G., Mellstedt, H., and Kiessling, R. (1993). Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas. Cancer Immunol. Immunother. 36, 191-197.
55. Hallermalm, K., Seki, K., Wei, C., Castelli, C., Rivoltini, L., Kiessling, R., and Levitskaya, J. (2001). Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. Blood 98, 1108-1115.
56. Hess, A. D., Thoburn, C., Chen, W., Miura, Y., and Van der Wall, E. (2001). The n-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self" epitope from a tumor-associated antigen. Clin. Immunol. 101, 67-76.
57. Hsieh, C. C., Chow, K. C., Fahn, H. J., Tsai, C. M., Li, W. Y., Huang, M. H., and Wang, L. S. (1998). Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. Ann. Thorac. Surg. 66, 1159-1163; discussion 1163-1164.
58. Hudziak, R. M., Lewis, G. D., Shalaby, M. R., Eessalu, T. E., Aggarwal, B. B., Ullrich, A., and Shepard, H. M. (1988). Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. Proc. Natl. Acad. Sci. USA 85, 5102-5106.
59. Ioannides, C. G., Fisk, B., Fan, D., Biddison, W. E., Wharton, J. T., and O'Brian, C. A. (1993). Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell. Immunol. 151, 225-234.
60. Ioannides, C. G., Freedman, R. S., Platsoucas, C. D., Rashed, S., and Kim, Y. P. (1991a). Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J. Immunol. 146, 1700-1707.
61. Ioannides, C. G., Platsoucas, C. D., Rashed, S., Wharton, J. T., Edwards, C. L., and Freedman, R. S. (1991b). Tumor cytolysis by lymphocytes infiltrating ovarian malignant a scites. Cancer Res. 51, 4257-4265.
62. Ishikawa, T., Kobayashi, M., Mai, M., Suzuki, T., and Ooi, A. (1997). Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am. J. Pathol. 151, 761-768.
63. Isola, J. J., Holli, K., Oksa, H., Teramoto, Y., and Kallioniemi, O. P. (1994). Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 73, 652-658.
64. Jager, D., Jager, E., and Knuth, A. (2001). Vaccination for malignant melanoma: Recent developments. Oncology 60, 1-7.
65. Kaklamanis, L., Leek, R., Koukourakis, M., Gatter, K. C., and Harris, A. L. (1995). Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res. 55, 5191-5194.
66. Kandl, H., Seymour, L., and Bezwoda, W. R. (1994). Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br. J. Cancer. 70, 739-742.
67. Kapitanovic, S., Radosevic, S., Kapitanovic, M., Andelinovic, S., Ferencic, Z., Tavassoli, M., Primorac, D., Sonicki, Z., Spaventi, S., Pavelic, K., and Spaventi, R. (1997). The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112, 1103-1113.
68. Kaplan, G., Walsh, G., Guido, L. S., Meyn, P., Burkhardt, R. A., Abalos, R. M., Barker, J., Frindt, P. A., Fajardo, T. T., Celona, R., et al. (1992). Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J. Exp. Med. 175, 1717-1728.
69. Kawashima, I., Hudson, S. J., Tsai, V., Southwood, S., Takesako, K., Appella, E., Sette, A., and Celis, E. (1998). The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol. 59, 1-14.
70. Kawashima, I., Tsai, V., Southwood, S., Takesako, K., Sette, A., and Celis, E. (1999). Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res. 59, 431-435.
71. Keogh, E., Fikes, J., Southwood, S., Celis, E., Chesnut, R., and Sette, A. (2001). Identification of new epitopes from four different tumor-associated antigens: Recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J. Immunol. 167, 787-796.
72. Klapper, L. N., Glathe, S., Vaisman, N., Hynes, N. E., Andrews, G. C., Sela, M., and Yarden, Y. (1999). The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl. Acad. Sci. USA 96, 4995-5000.
73. Klapper, L. N., Kirschbaum, M. H., Sela, M., and Yarden, Y. (2000). Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 77, 25-79.
74. Knutson, K. L., Schiffman, K., and Disis, M. L. (2001). Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107, 477-484.
75. Kobayashi, H., Wood, M., Song, Y., Appella, E., and Celis, E. (2000). Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res. 60, 5228-5236.
76. Kono, K., Halapi, E., Hising, C., Petersson, M., Gerdin, E., Vanky, E, and Kiessling, R. (1997). Mechanisms of escape from CD8+ T-cell clones specific for the HER-2/neu proto-oncogene expressed in ovarian carcinomas: Related and unrelated to decreased MHC class 1 expression. Int. J. Cancer 70, 112-119.
77. Kono, K., Rongcun, Y., Charo, J., Ichihara, F., Celis, E., Sette, A., Appella, E., Sekikawa, T., Matsumoto, Y., and Kiessling, R. (1998). Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int. J. Cancer 78, 202-208.
78. Kuhns, J. J., Batalia, M. A., Yan, S., and Collins, E. J. (1999). Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide. J. Biol. Chem. 274, 36,422-36,427.
79. Kurt, R. A., Whitaker, R., Baher, A., Seung, S., and Urba, W. J. (2000). Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice. Int. J. Cancer 87, 688-694.
80. Latil, A., Baron, J. C., Cussenot, O., Fournier, G., Boccon-Gibod, L., Le Duc, A., and Lidereau, R. (1994). Oncogene amplifications in early-stage human prostate carcinomas. Int. J. Cancer 59, 637-638.
81. Lau, R., Wang, E, Jeffery, G., Marty, V., Kuniyoshi, J., Bade, E., Ryback, M. E., and Weber, J. (2001). Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J. Immunother. 24, 66-78.
82. Lichtenstein, A., Berenson, J., Gera, J. F., Waldburger, K., Martinez-Maza, O., and Berek, J. S. (1990). Resistance of human ovarian caner cells to tumor necrosis factor and lymphokine-activated killer cells: Correlation with expression of HER2/neu oncogenes. Cancer Res. 50, 7364-7370.
83. Lin, W., Sanchez, H. B., Deerinck, T., Morris, J. K., Ellisman, M., and Lee, K. F. (2000). Aberrant development of motor axons and neuromuscular synapses in erbB2-deficient mice. Proc. Natl. Acad. Sci. USA 97, 1299-1304.
84. Linehan, D. C., Goedegebuure, P. S., Peoples, G. E., Rogers, S. O., and Eberlein, T. J. (1995). Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J. Immunol. 155, 4486-4491.
85. Lollini, P. L., Nicoletti, G., Landuzzi, L., De Giovanni, C., Rossi, I., Di Carlo, E., Musiani, P., Muller, W. J., and Nanni, P. (1998). Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. Int. J. Cancer 77, 937-941.
86. Lotze, M. T., Shurin, M., Davis, I., Amoscato, A., and Storkus, W. J. (1997). Dendritic cell based therapy of cancer. Adv. Exp. Med. Biol. 417, 551-569.
87. Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., and Pollak, M. (2001). Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. 93, 1852-1857.
88. Ludewig, B., Ochsenbein, A. F., Odermatt, B., Paulin, D., Hengartner, H., and Zinkernagel, R. M. (2000). Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. 191, 795-804.
89. Lustgarten, J., Theobald, M., Labadie, C., LaFace, D., Peterson, P., Disis, M. L., Cheever, M. A., and Sherman, L. A. (1997). Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. Hum. Immunol. 52, 109-118.
90. Macpherson, A. J., Lamarre, A., McCoy, K., Harriman, G. R., Odermatt, B., Dougan, G., Hengartner, H., and Zinkernagel, R. M. (2001). IgA production without mu or delta chain expression in developing B cells. Nat. Immunol. 2, 625-631.
91. Menard, S., Casalini, P., Campiglio, M., Pupa, S., Agresti, R., and Tagliabue, E. (2001). HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann. Oncol. 12, S15-S19.
92. Monach, P. A., Schreiber, H., and Rowley, D. A. (1993). CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation 55, 1356-1361.
93. Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., and Leder, P. (1988). Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54, 105-115.
94. Murphy, G. P., Tjoa, B. A., Simmons, S. J., Jarisch, J., Bowes, V. A., Ragde, H., Rogers, M., Elgamal, A., Kenny, G. M., Cobb, O. E., Ireton, R. C., Troychak, M. J., Salgaller, M. L., and Boynton, A. L. (1999). Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38, 73-78.
95. Nagata, Y., Furugen, R., Hiasa, A., Ikeda, H., Ohta, N., Furukawa, K., Nakamura, H., Kanematsu, T., and Shiku, H. (1997). Peptides derived from a wild-type murine protooncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J. Immunol. 159, 1336-1343.
96. Nagy, P., Jenei, A., Damjanovich, S., Jovin, T. M., and Szolosi, J. (1999). Complexity of signal transduction mediated by ErbB2: Clues to the potential of receptor-targeted cancer therapy. Pathol. Oncol. Res. 5, 255-271.
97. Nanni, P., Nicoletti, G., De Giovanni, C., Landuzzi, L., Di Carlo, E., Cavallo, F., Pupa, S. M., Rossi, I., Colombo, M. P., Ricci, C., Astolfi, A., Musiani, P., Forni, G., and Lollini, P. L. (2001). Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med. 194, 1195-1205.
98. Ndubisi, B., Sanz, S., Lu, L., Podczaski, E., Benrubi, G., and Masood, S. (1997). The prognostic value of HER-2/neu oncogene in cervical cancer. Ann. Clin. Lab. Sci. 27, 396-401.
99. Neal, D. E., Marsh, C., Bennett, M. K., Abel, P. D., Hall, R. R., Sainsbury, J. R., and Harris, A. L. (1985). Epidermal-growth-factor receptors in human bladder cancer: Comparison of invasive and superficial tumours. Lancet 1, 366-368.
100. Ossendorp, E, Mengede, E., Camps, M., Filius, R., and Melief, C. J. (1998). Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187, 693-702.
101. Pamer, E., and Cresswell, P. (1998). Mechanisms of MHC Class I-restricted antigen processing. Annu. Rev. Immunol. 16, 323-358.
102. Panina-Bordignon, P., Tan, A., Termijtelen, A., Demotz, S., Corradin, G., and Lanzavecchia, A. (1989). Universally immunogenic T cell epitopes: Promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19, 2237-2242.
103. Paz, P., Brouwenstijn, N., Perry, R., and Shastri, N. (1999). Discrete proteolytic intermediates in the MHC class I antigen processing pathway and MHC I-dependent peptide trimming in the ER. Immunity 11, 241-251.
104. Peoples, G. E., Goedegebuure, P. S., Andrews, J. V., Schoof, D. D., and Eberlein, T. J. (1993). HLA-A2 presents shared tumor-associated antigens derived form endogenous proteins in ovarian cancer. J. Immunol. 151, 5481-5491.
105. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., and Eberlein, T. J. (1995a). Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA 92, 432-436.
106. Peoples, G. E., Smith, R. C., Linehan, D. C., Yoshino, I., Goedegebuure, P. S., and Eberlein, T. J. (1995b). Shared T cell epitopes in epithelial tumors. Cell. Immunol. 164, 279-286.
107. Peoples, G. E., Yoshino, I., Douville, C. C., Andrews, J. V., Goedegebuure, P. S., and Eberlein, T. J. (1994). TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers. J. Immunol. 152, 4993-4999.
108. Persons, D. L., Borelli, K. A., and Hsu, P. H. (1997). Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod. Pathol. 10, 720-727.
109. Piechocki, M. P., Pilon, S. A., and Wei, W. Z. (2001a). Complementary antitumor immunity induced by plasmid dna encoding secreted and cytoplasmic human erbb-2. J. Immunol. 167, 3367-3374.
110. Piechocki, M. P., Pilon, S. A., Kelly, C., and Wei, W. Z. (2001b). Degradation signals in ErbB-2 dictate proteasomal processing and immunogenicity and resist protection by cis glycinealanine repeat. Cell Immunol. 212, 138-149.
111. Pilon, S. A., Piechocki, M. P., and Wei, W. Z. (2001). Vaccination with cytoplasmic erbb-2 dna protects mice from mammary tumor growth without anti-erbb-2 antibody. J. Immunol. 167, 3201-3206.
112. Prenzel, N., Fischer, O. M., Streit, S., Hart, S., and Ullrich, A. (2001). The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer 8, 11-31.
113. Prenzel, N., Zwick, E., Leserer, M., and Ullrich, A. (2000). Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: Convergence pont for signal integration and diversification. Breast Cancer Res. 2, 184-190.
114. Press, M. F., Cordon-Cardo, C., and Slamon, D. J. (1990). Expression of the HER-2/neu protooncogene in normal human adult and fetal tissues. Oncogene 5, 953-962.
115. Pupa, S. M., Menard, S., Andreola, S., and Colnaghi, M. I. (1993). Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res. 53, 5864-5866.
116. Qin, Z., Richter, G., Schuler, T., Ibe, S., Cao, X., and Blankenstein, T. (1998). B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 4, 627-630.
117. Quirke, P., Pickles, A., Tuzi, N. L., Mohamdee, O., and Gullick, W. J. (1989). Pattern of expression of c-erbB-2 oncoprotein in human fetuses. Br. J. Cancer 60, 64-69.
118. Ratcliffe, N., Wells, W., Wheeler, K., and Memoli, V. (1997). The combination of in situ hybridization and immunohistochemical analysis: An evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium. Mod. Pathol. 10, 1247-1252.
119. Reilly, R. T., Machiels, J. P., Emens, L. A., Ercolini, A. M., Okoye, F. I., Lei, R. Y., Weintraub, D., and Jaffee, E. M. (2001). The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res. 61, 880-883.
120. Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., and Goldberg, A. L. (1994). Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78, 761-771.
121. Rongcun, Y., Salazar-Onfray, E, Charo, J., Malmberg, K. J., Evrin, K., Maes, H., Kono, K., Hising, C., Petersson, M., Larsson, O., Lan, L., Appella, E., Sette, A., Celis, E., and Kiessling, R. (1999). Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J. Immunol. 163, 1037-1044.
122. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. (1998). Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma [see comments]. Nat. Med. 4, 321-327.
123. Rotter, M., Block, T., Busch, R., Thanner, S., and Hofler, H. (1992). Expression of HER-2/neu in renal-cell carcinoma. Correlation with histologic subtypes and differentiation. Int. J. Cancer. 52, 213-217.
124. Rovero, S., Amici, A., Carlo, E. D., Bei, R., Nanni, P., Quaglino, E., Porcedda, P., Boggio, K., Smorlesi, A., Lollini, P. L., Landuzzi, L., Colombo, M. P., Giovarelli, M., Musiani, P., and Forni, G. (2000). DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 165, 5133-5142.
125. Rovero, S., Boggio, K., Carlo, E. D., Amici, A., Quaglino, E., Porcedda, P., Musiani, P., and Forni, G. (2001). Insertion of the DNA for the 163-171 peptide of IL 1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice. Gene Ther. 8, 447-452.
126. Rubin, I., and Yarden, Y. (2001). The basic biology of HER2. Ann. Oncol. 12, S3-S8.
127. Scardino, A., Alves, P., Gross, D. A., Tourdot, S., Graff-Dubois, S., Angevin, E., Firat, H., Chouaib, S., Lemonnier, F., Nadler, L. M., Cardoso, A. A., and Kosmatopoulos, K. (2001). Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur. J. Immunol. 31, 3261-3270.
128. Schuler, G., and Steinman, R. M. (1997). Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186, 1183-1187.
129. Scott, A. M., Lee, F. T., Hopkins, W., Cebon, J. S., Wheatley, J. M., Liu, Z., Smyth, F. E., Murone, C., Sturrock, S., MacGregor, D., Hanai, N., Inoue, K., Yamasaki, M., Brechbiel, M. W., Davis, I. D., Murphy, R., Hannah, A., Lim-Joon, M., Chan, T., Chong, G., Ritter, G., Hoffman, E. W., Burgess, A. W., and Old, L. J. (2001). Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: Results of a phase I trial. J. Clin. Oncol. 19, 3976-3987.
130. Seliger, B., Maeurer, M. J., and Ferrone, S. (1997). TAP off - Tumors on. Immunol. Today 18, 292-299.
131. Seliger, B., Maeurer, M. J., and Ferrone, S. (2000a). Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21, 455-464.
132. Seliger, B., Rongcun, Y., Atkins, D., Hammers, S., Huber, C., Storkel, S., and Kiessling, R. (2000b). HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int. J. Cancer 87, 349-359.
133. Seliger, B., Wollscheid, U., Momburg, F., Blankenstein, T., and Huber, C. (2001). Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res. 61, 1095-1099.
134. Shak, S. (1999). Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin. Oncol. 26, 71-77.
135. Sharma, A. K., Kuhns, J. J., Yan, S., Friedline, R. H., Long, B., Tisch, R., and Collins, E. J. (2001). Class I major histocompatibility complex anchor substitutions after the conformation of T cell receptor contacts. J. Biol. Chem. 276, 21,443-21,449.
136. Shepard, H. M., and Lewis, G. D. (1988). Resistance of tumor cells to tumor necrosis factor. J. Clin. Immunol. 8, 333-341.
137. Shiku, H., Wang, L., Ikuta, Y., Okugawa, T., Schmitt, M., Gu, X., Akiyoshi, K., Sunamoto, J., and Nakamura, H. (2000). Development of a cancer vaccine: Peptides, proteins, and DNA. Cancer Chemother. Pharmacol. 46, S77-S82.
138. Skipper, J. C., Gulden, P. H., Hendrickson, R. C., Harthun, N., Caldwell, J. A., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., and Slingluff, C. L., Jr. (1999). Mass-spectrometric evalution of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int. J. Cancer 82, 669-677.
139. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
140. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712.
141. Sliwkowski, M. X., Lofgren, J. A., Lewis, G. D., Hotaling, T. E., Fendly, B. M., and Fox, J. A. (1999). Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26, 60-70.
142. Sotiriadou, R., Perez, S. A., Gritzapis, A. D., Sotiropoulou, P. A., Echner, H., Heinzel, S., Mamalaki, A., Pawelec, G., Voelter, W., Baxevanis, C. N., and Papamichail, M. (2001). Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br. J. Cancer 85, 1527-1534.
143. Srivastava, P. K., and Udono, H. (1994). Heat shock protein-peptide complexes in cancer immunotherapy. Curr. Opin. Immunol. 6, 728-732.
144. Suda, Y., Aizawa, S., Furuta, Y., Yagi, T., Ikawa, Y., Saitoh, K., Yamada, Y., Toyoshima, K., and Yamamoto, T. (1990). Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with the mutated gene (Val659-Glu659). EMBO J. 9, 181-190.
145. Szollosi, J., Balazs, M., Feuerstein, B. G., Benz, C. C., and Waldman, E M. (1995). ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res. 55, 5400-5407.
146. Theobald, M., Ruppert, T., Kuckelkorn, U., Hernandez, J., Haussler, A., Ferreira, E. A., Liewer, U., Biggs, J., Levine, A. J., Huber, C., Koszinowski, U. H., Kloetzel, P. M., and Sherman, L. A. (1998). The sequence alteration associated with a mutational hotspot in p5 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J. Exp. Med. 188, 1017-1028.
147. Thurnher, M., Klocker, H., Papesh, C., Ramoner, R., Radmayr, C., Hobisch, A., Gastl, G., Romani, N., Ebner, S., Bock, G., and Bartsch, G. (1997). Dendritic cells for the immunotherapy of renal cell carcinoma. Urol. Int. 59, 1-5.
148. Tsai, C. M., Chang, K. T., Wu, L. H., Chen, J. Y., Gazdar, A. F., Mitsudomi, T., Chen, M. H., and Perng, R. P. (1996a). Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res. 56, 206-209.
149. Tsai, C. M., Levitzki, A., Wu, L. H., Chang, K. T., Cheng, C. C., Gazit, A., and Perng, R. P. (1996b). Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res. 56, 1068-1074.
150. Tureci, O., Sahin, U., and Pfreundschuh, M. (1997). Serological analysis of human tumor antigens: Molecular definition and implications. Mol. Med. Today 3, 342-349.
151. Tuttle, T. M., Anderson, B. W., Thompson, W. E., Lee, J. E., Sahin, A., Smith, T. L., Grabstein, K. H., Wharton, J. T., Ioannides, C. G., and Murray, J. L. (1998). Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. Clin. Cancer Res. 4, 2015-2024.
152. Tzahar, E., and Yarden, Y. (1998). The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands. Biochim. Biopbys. Acta 1377, M25-M37.
153. Valeron, P. F., Chirino, R., Fernandez, L., Torres, S., Navarro, D., Aguiar, J., Cabrera, J. J., Diaz-Chico, B. N., and Diaz-Chico, J. C. (1996). Validation of a differential PCR and an ELISA procedure in studying HER-2/neu status in breast cancer. Int. J. Cancer 65, 129-133.
154. van der Geer, P., Hunter, T., and Lindberg, R. A. (1994). Receptor protein-tyrosine kinases and their signal transduction pathways. Annu. Rev. Cell Biol. 10, 251-337.
155. Vanky, F., Klein, E., Willems, J., Book, K., Ivert, T., Peterffy, A., Nilsonne, U., and Kreicbergs, A. (1987a). Lysis of autologous tumor cells by blood lymphocytes activated in autologous mixed lymphocyte tumor cell culture - No correlation with the postsurgical clinical course. Cancer Immunol. Immunother. 24, 180-183.
156. Vanky, F., Roberts, T., Klein, E., and Willems, J. (1987b). Auto-tumor immunity in patients with solid tumors: participation of CD3 complex and MHC class I antigens in the lytic interaction. Immunol. Lett. 16, 21-26.
157. Weidner, U., Peter, S., Strohmeyer, T., Hussnatter, R., Ackermann, R., and Sies, H. (1990). Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma. Cancer Res. 50, 4504-4509.
158. Wu, J. T., Astill, M. E., and Zhang, P. (1993). Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: Correlation with tumor markets. J. Clin. Lab. Anal. 7, 31-40.
159. Yamanaka, Y., Friess, H., Kobrin, M. S., Buchler, M., Kunz, J., Beger, H. G., and Korc, M. (1993). Overexpression of HER2/neu oncogene in human pancreatic carcinoma. [see comments] Hum. Pathol. 24, 1127-1134.
160. Yang, B., Hahn, Y. S., Hahn, C. S., and Braciale, T. J. (1996). The requirement for proteasome activity class I major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen. J. Exp. Med. 183, 1545-1552.
161. Yee, C., Thompson, J. A., Roche, P., Byrd, D. R., Lee, P. P., Piepkorn, M., Kenyon, K., Davis, M. M., Riddell, S. R., and Greenberg, P. D. (2000). Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of t cell-mediated vitiligo. J. Exp. Med. 192, 1637-1644.
162. Yoshino, I., Goedegebuure, P. S., Peoples, G. E., Parikh, A. S., DiMaio, J. M., Lyerly, H. K., Gazdar, A. F., and Eberlein, T. J. (1994a). HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res. 54, 3387-3390.
163. Yoshino, I., Peoples, G. E., Goedegebuure, P. S., Maziarz, R., and Eberlein, T. J. (1994b). Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J. Immunol. 152, 2393-2400.
164. Zaks, T. Z., and Rosenberg, S. A. (1998). Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res. 58, 4902-4908.
165. Zeng, G., Touloukian, C. E., Wang, X., Restifo, N. P., Rosenberg, S. A., and Wang, R. E (2000). Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J. Immunol. 165, 1153-1159.
166. Zhao, Y. Y., Sawyer, D. R., Baliga, R. R., Opel, D. J., Hah, X., Marchionni, M. A., and Kelly, R. A. (1998). Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J. Biol. Chem. 273, 10, 261-10, 269.
167. Zhou, B. P., Hu, M. C., Miller, S. A., Yu, Z., Xia, W., Lin, S. Y., and Hung, M. C. (2000). HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J. Biol. Chem. 275, 8027-8031.
168. Zinkernagel, R. M., and Doherty, P. C. (1974). Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature. 248, 701-702.
169. zum Buschenfelde, C. M., Metzger, J., Hermann, C., Nicklisch, N., Peschel, C., and Bernhard, H. (2001). The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells. J. Immunol. 167, 1712-1719.
170. zum Buschenfelde, C. M., Hermann, C., Schmidt, B., Peschel, C., and Bernhard, H. (2002). Antihuman Epidermal Growth Factor Receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of Class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 62, 2244-2247.